Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences.
J Psychopharmacol. 1996 Jan;10(2):157-61. doi: 10.1177/026988119601000212.
In the present study, the effects of chronic lithium pre-treatment (30 days) on penile erection (PE) induced by bromocriptine were investigated in rats. Intraperitoneal administration of the dopamine receptor agonist, bromocriptine (4-32 mg/kg) induced PE in a biphasic manner. The maximum response was obtained with 8 mg/kg of bromocriptine and the effect was decreased with increasing doses of the drug from 8 to 32 mg/kg. When animals were pre-treated with different doses of the D-1 dopamine receptor antagonist, SCH 23390, or the D-2 dopamine receptor antagonist, sulpiride, the PE response was decreased. The response induced by bromocriptine (4-32mg/kg) was reduced in animals pre-treated with chronic lithium. SCH 23390 did not produce a larger inhibitory effect on the bromocriptine response in animals pre-treated with chronic lithium, but the inhibitory effect of sulpiride was increased in this condition. It is concluded that chronic lithium treatment may alter the D-1/D-2 receptor activity and inhibit bromocriptine-induced PE.
在本研究中，我们观察了慢性锂预处理（30 天）对溴隐亭诱导的阴茎勃起（PE）的影响。腹腔内给予多巴胺受体激动剂溴隐亭（4-32mg/kg）呈双相诱导 PE。溴隐亭 8mg/kg 时获得最大反应，随着药物剂量从 8mg/kg 增加到 32mg/kg，效果降低。当动物预先用不同剂量的 D-1 多巴胺受体拮抗剂 SCH 23390 或 D-2 多巴胺受体拮抗剂舒必利预处理时，PE 反应减少。在慢性锂预处理的动物中，溴隐亭（4-32mg/kg）诱导的反应减少。SCH 23390 预处理后，对慢性锂预处理动物中溴隐亭反应没有产生更大的抑制作用，但在这种情况下，舒必利的抑制作用增加。综上所述，慢性锂处理可能改变 D-1/D-2 受体活性并抑制溴隐亭诱导的 PE。
